# Dynaris

We set new standard in oxygen therapy; 7 patents, FDA, superior therapy, & more 

## Elevator pitch
Founded in 2014, Dynaris has developed a new standard in oxygen delivery devices. Its patented and FDA Cleared Apogee and cannula are the first in a line of products designed to improve patient health, eliminate oxygen waste, reduce prescription costs, and provide a more comfortable therapeutic experience.

- Canonical URL: https://wefunder.com/dynaris
- Entity ID: wefunder:company:88979
- Last updated: 2026-06-22T05:03:21Z
- Generated at: 2026-06-23T00:21:33Z

## Quick facts
- FDA 510 (K), EUA, ISO-13485 Quality System, FDA registered manufacturing in-house, Ready to go!
- 5.9 million patients on oxygen in the U.S. alone growing to over 7 million patients in 2023.
- Protected by 7 U.S. Patents, more pending, foreign patents pending.
- Experienced team with a history of success, from concept through acquisition. CEO has 28 patents
- Superior oxygen therapy for patients. Sets a new therapeutic standard for oxygen patients.
- Oxygen therapies are expanding to other areas; i.e. cluster headaches and wound healing treatments
- Additional products in development expand our technologies into other therapeutic market segments.

## Active fundraises
- wefunder:fundraise:46410: 4(a)(6) successful (USD)
- wefunder:fundraise:46636: 4(a)(6) successful (USD)

## Story
This slide contains forward-looking projections that cannot be guaranteed.

## Team
- Lawrence C. Spector (Managing Member)
- Timm Eckenroth (Design Engineering Manager)
- Ben Stockman (Software Engineering Manager)
- Ryan Lundgren (Media Manager)
- Oscar Carrillo (Scientific Advisor)
- Tabitha Cacheris (Biomedical Engineer)
- Joshua Samuel (Biomedical Engineer)
- Deb Aylsworth (Business and Accounting Manager)
- Alonzo C. Aylsworth (founder)

## Q&A
- Q: Currently a lot of patients can’t handle pulse flow and require continuous oxygen. It seems they don’t get enough oxygen for their needs with current pulse flow technology. Does the Apogee overcome this limitation? In other words I’d like know if patients who can only use continuous flow current will be able to use the Apogee system? Can the Apogee support Pulse oximetry based adjustments of O2 flow for the patients that require it?
- Q: You are also developing a stationary system. Presumably this will be covered under the same existing 510 (K)? How far along are you in developing this system and what costs do you foresee associated with its development? Are the stationary units for patient’s home or hospitals or both? The value proposition of The Dynamic Oxygen System is strongest in an ambulatory setting. The primary benefit IMO is the oxygen lasts longer. Do you feel it may be more difficult to sell the stationary system given that the value proposition is not as strong? To what extent can the marketing efforts for the portable Apogee system be leveraged to sell the stationary Select O2 system? Apogee is marketed to patients directly, home care dealers, and doctors. Are there additional players like hospital administrators that you need to target to sell the stationary Select O2 system?
- Q: How difficult will it be to overcome the status quo? Are there significant switching costs for patients, home care dealers, and doctors? For instance, are there financial incentives for insurers, home care dealers and doctors to stick with existing competitors? What about the money that patients have already spent on existing systems? Will the doctors see this as sufficient improvement to switch their patients?
- Q: I was wondering if there was a place online or elsewhere where there are patient reviews, feedback, or general reactions. I realize there have been few sales to date, but it would be great to hear from the patients, if possible.
- Q: Who are existing competitors and can they respond?
- Q: I am from Hong Kong, as an investor, could we explore bringing this to my part of the world too?
- Q: I am very intrigued by the proposition and love the product itself, but have a couple of follow-up questions I did not see addressed (or possibly missed). (1) You mention you have EUA currently, but what is your timeline for full FDA approval and do you see any impact to your path to profitability mentioned below only operating under an EUA for the foreseeable future? (2) Your Schedule C calls out you have ~500K of inventory on hand but no revenue for the preceding 24 months. Are these units actively being marketed and sold or is there a milestone/approval preventing them from being sold? (3) Your revenue projections predict ~6.5 million in revenue for the FY21 year with us now in the 4th month of that year. How will you ramp up sales that quickly? Do you have an existing pipeline of customers or LOI for B2B sales 4) Would this device be covered by private insurance or Medicare/Medicaid, or will it need to be purchased by the individual. Thank you
- Q: Are you all planning on remaining an LLC for tax purposes, and do you anticipate becoming profitable any time soon?
- Q: Hello, Can your device be adapted for use with CPAP (Sleep apnoea) machines? i.e. direct air to open nostril leading need for lower air pressure & less noise leading to better sleep quality? By pumping more O2 to open nostril does it not cause drying out and irritation issues?
- Q: Hello, I love the idea and I am sure it would help with this COVID pandemic in which some countries are struggling with the lack of oxygen available. My question is on the investment terms as I am not familiar with this. What prevents you from setting a very high valuation ?